Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Can you imagine running an online store without being able to contact your customers or process their payments? Most of the time, collecting this crucial data is relatively seamless through a simple ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

It is hard to productionalize data science use cases, especially because the journey from experimentation is lacking standardisation. Thus, this project aims at boosting, scalability, productivity and ...

Your browser does not support the audio element. Vertex AI Workbench is a managed Jupyter environment in Google Cloud. It ships with native integration with BigQuery ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals made its name and fortune by developing ever more effective medicines for the rare disease cystic fibrosis. On Monday, the biotechnology company disclosed two setbacks that ...

Vertex is a brand with a storied past. It was one of the watchmakers that provided watches to the British Ministry of Defence (MoD) during World War II. The watch we are looking at today, the Vertex ...

Vertex Rail Technologies opened in Wilmington in 2014 with promises of over 1,300 jobs and a $60 million investment. Despite initial optimism and orders, the company faced setbacks including federal ...

Pittsburgh-based pharmaceutical firm Viatris on Thursday said a pain drug it’s been developing succeeded in two large clinical trials, setting the stage for an approval filing later this year. The ...